BRPI0607043A2 - lacosamida para terapia de adição - Google Patents

lacosamida para terapia de adição

Info

Publication number
BRPI0607043A2
BRPI0607043A2 BRPI0607043-4A BRPI0607043A BRPI0607043A2 BR PI0607043 A2 BRPI0607043 A2 BR PI0607043A2 BR PI0607043 A BRPI0607043 A BR PI0607043A BR PI0607043 A2 BRPI0607043 A2 BR PI0607043A2
Authority
BR
Brazil
Prior art keywords
lacosamide
addiction therapy
therapy
addiction
addition therapy
Prior art date
Application number
BRPI0607043-4A
Other languages
English (en)
Inventor
Thomas Stoehr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BRPI0607043A2 publication Critical patent/BRPI0607043A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LACOSAMIDA PARA TERAPIA DE ADIçãO. A presente invenção refere-se ao uso de uma classe de compostos peptídicos para a prevenção, alívio e/ou tratamento de uma doença que seja tratada com antipsicóticos, em particular psicose, mais particularmente esquizofrenia,em uma terapia de adição a pelo menos um antipsicótico.
BRPI0607043-4A 2005-01-28 2006-01-27 lacosamida para terapia de adição BRPI0607043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
BRPI0607043A2 true BRPI0607043A2 (pt) 2009-08-04

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607043-4A BRPI0607043A2 (pt) 2005-01-28 2006-01-27 lacosamida para terapia de adição

Country Status (12)

Country Link
EP (1) EP1841417A2 (pt)
JP (1) JP2008528532A (pt)
KR (1) KR20070096058A (pt)
AR (1) AR057643A1 (pt)
AU (1) AU2006208630B2 (pt)
BR (1) BRPI0607043A2 (pt)
CA (1) CA2595330A1 (pt)
EA (1) EA015566B1 (pt)
IL (1) IL183973A0 (pt)
MX (1) MX2007009070A (pt)
NO (1) NO20074361L (pt)
WO (1) WO2006079547A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Also Published As

Publication number Publication date
CA2595330A1 (en) 2006-08-03
EA015566B1 (ru) 2011-10-31
EA200701594A1 (ru) 2008-02-28
AR057643A1 (es) 2007-12-12
WO2006079547A2 (en) 2006-08-03
EP1841417A2 (en) 2007-10-10
AU2006208630B2 (en) 2011-09-29
IL183973A0 (en) 2008-12-29
KR20070096058A (ko) 2007-10-01
JP2008528532A (ja) 2008-07-31
NO20074361L (no) 2007-10-26
AU2006208630A1 (en) 2006-08-03
WO2006079547A3 (en) 2006-09-21
MX2007009070A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TNSN08400A1 (en) Organic compounds and their uses
NO20074361L (no) Lacosamid for "add-on"-terapi
WO2008131298A3 (en) Prevention and treatment of cerebral amyloid angiopathy
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
CR20130455A (es) Composiciones para el tratamiento de tumores
BRPI0517273A (pt) composição baseada em bactéria probiótica e o uso desta na prevenção e/ou tratamento de patologias e/ou infecções respiratórias e no aperfeiçoamento da funcionalidade intestinal
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
TNSN08496A1 (en) Aminothiazoles and their uses
BRPI0510947A (pt) tratamento de doença respiratória
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
EA200901613A1 (ru) Макроциклы и их применение
AR064219A1 (es) Cuerpo moldeado que contiene titanio
WO2005118636A3 (en) Tgf derepressors and uses related thereto
TW200637538A (en) Lacosamide for add-on-therapy
UY29417A1 (es) Agentes endoparasiticidas
ATE511512T1 (de) Olanzapinpamoat-dihydrat

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.